首页> 外国专利> Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof

Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof

机译:具有改善的细胞毒性和产量的抗EGFRvIII SCFVS,基于其的免疫毒素及其使用方法

摘要

The invention provides antibodies to a mutant form of the epidermal growth factor receptor known as EGFRvIII found only or primarily on the surface of glioblastoma cells, and on cells of breast, ovarian and non-small cell lung carcinomas. The antibodies provided by the invention have the complementarity determining regions ("CDRs") of the scFv designated MR1, but with mutations at positions 98 and 99 in the CDR3 of the heavy chain variable region and, optionally, in other CDRs. In particular, the invention provides an antibody, designated MR1-1, which mutates MR1 in the CDR3 of the VH and VL chains. The invention provides additional antibodies in which MR1 is mutated in the CDR1 and 2 of VH or VL, or both.
机译:本发明提供了针对表皮生长因子受体的突变形式的抗体,称为EGFRvIII,其仅或主要存在于成胶质细胞瘤细胞的表面以及乳腺癌,卵巢癌和非小细胞肺癌的细胞上。本发明提供的抗体具有scFv的互补决定区(“ CDR”),称为MR1,但是在重链可变区的CDR3以及任选地在其他CDR中的98和99位具有突变。特别地,本发明提供了一种命名为MR1-1的抗体,其使VH和VL链的CDR3中的MR1突变。本发明提供了另外的抗体,其中MR1在VH或VL或两者的CDR1和2中突变。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号